Interviews - The shortcomings of Alzheimer’s research stems from a fundamental belief that removing amyloid is the treatment approach. The research community has been led astray by … Continue Reading
Read nowInsights - Stakeholders in Alzheimer’s Disease have been fixated on the amyloid thesis, which has resulted in underwhelming results for the past decade. 2020 is shaping up … Continue Reading
PremiumInsights - Below we’ve outlined our watchlist with 3 main names that we think will outperform in the new year. The 3 names are Iovance, Xenon and … Continue Reading
PremiumInsights - Affimed (AFMD) had a call discussing Q3 results this morning. We were looking to see if anything had materially changed, especially after Affimed announced a … Continue Reading
PremiumInsights - This morning, the FDA released briefing documents that will be used as guidance by the panel members of the advisory committee (ADCOM) for Amarin’s Vascepa this Thursday. The package … Continue Reading
Read nowInsights - Last year we covered Affimed’s (AFMD) early clinical data for AFM-13 as a monotherapy and combination with Keytruda (read details here and here). In this note, we’ll cover … Continue Reading
PremiumInsights - Yesterday after market, Achillion (ACHN) released data and a strategic update, including interim data for C3G and PNH indications. The stock was down 20% leading up to … Continue Reading
Read now
